MedTech AI Startup AcuityMD Raises $80M in New Funding

The Boston-based company, which serves 16 of the top 20 MedTech firms globally, is deploying fresh capital to accelerate agentic AI for commercial teams and extend its platform beyond sales into the full product lifecycle.

AcuityMD, the AI platform for MedTech, announced April 21 an $80 million funding round to expand its platform with advanced AI capabilities. The Series C was led by existing investor StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. AcuityMD has now raised more than $160 million in total and is valued at $955 million.

The platform is currently used by more than 400 MedTech companies, including 16 of the top 20 globally, and has helped customers identify over $34 billion in commercial pipeline to date.

ALSO READ: NeoCognition Raises $40M Seed to Build Human-Like AI Agents

The company’s core offering addresses a structural problem in MedTech commercialization. Commercial intelligence that MedTech companies need is scattered across claims databases, FDA filings, government records, and market signals that no single company can assemble independently. AcuityMD aggregates this into a proprietary knowledge graph, mapping physicians, facilities, networks, procedures, reimbursement dynamics, and the relationships between them, aligned with each customer’s internal contracting data, product indications, territory structure, and CRM activity.

AcuityAI, now in open beta, is built on that foundation. It connects AcuityMD’s ontology with a company’s business context and each sales representative’s specific situation to surface answers that broader, horizontal AI platforms cannot replicate.

“AcuityAI has given our commercial team sharper answers, faster,” said Mark Edwards, senior director of sales operations at Kuros Biosciences, in the company’s press release. “Insights that used to take hours are now surfaced right when our reps need them, leading to richer conversations and opportunities we might otherwise have missed.”

The new capital will fund three priorities: accelerating agentic AI capabilities for commercial roles including sales reps, leadership, and marketing teams; deepening the MedTech ontology that underpins the platform’s data model; and expanding the platform beyond commercial functions to support the broader product lifecycle.

“AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made,” said CEO and co-founder Mike Monovoukas in the press release. “AcuityMD is that context layer.”

Hunter Somerville, partner at StepStone Group, noted that the company’s depth of data represents a meaningful competitive advantage that grows more valuable as AI capabilities advance.

Disclaimer: This news is based on publicly available information. NervNow has not independently verified the claims made therein.

MORE ON STARTUPS & FUNDING
Lawyered Raises $2.5M Pre-Series A for Legal AI Growth
Bezos’ Project Prometheus Nears $10B Raise at $38B Valuation
Amazon Teams Up With Anthropic in $100 Billion Deal